Lisata Therapeutics Acquires Marea to Secure Antibody Pipeline

To fund the integration and development of its expanded portfolio, Lisata simultaneously entered a private placement agreement to sell Series C non-voting convertible stock. This financing round is expected to generate $225 million in gross proceeds. The capital infusion is earmarked specifically to accelerate the clinical advancement of MAR001/005 and MAR002, the two primary antibody therapies inherited from Marea.

These assets are currently undergoing trials, with management projecting that topline data will be available by the fourth quarter of 2027. By securing these late-stage development programs, Lisata aims to bolster its pipeline despite the broader market pressures that have hampered its share price performance throughout the current calendar year.